Maxim lowered the firm’s price target on cbdMD (YCBD) to $3 from $16 but keeps a Buy rating on the shares. The firm cites the company Q2 results missing its estimates on earnings and revenue along with its “significant share dilution”, the analyst tells investors in a research note. Maxim adds however that with improved marketing execution, a cleaner capital structure, and growing momentum across its diversified product portfolio, it believes that cbdMD is positioned to return to sales growth.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YCBD: